Crescendo Biologics Ltd. Raises $70 Million (€57 Million) in Series B FinancingRound led by Andera Partners with significant investments by Quan Capital and existing investors, largest disclosed Series B financing in the European Biotech sector in 2018 CAMBRIDGE, England, April 30, 2018-- Crescendo Biologics Ltd (Crescendo) the developer of multi-functional biologics with a focus on novel targeted T-cell engagers, announced today that it has completed a $70 million (€57 million) Series B financing.